Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Technically very strong on excellent volume.
This, plus all the positive media coverage, strongly suggests higher prices are on the horizon for Abattis.
A very exciting growth stock and clearly a stock for one's cannabis portfolio.
LOL ... we are the two sides of the same coin. Your farewell is my ascension. You are closer to me than I want ...
Good luck to all
2018
Nice to see it hold the weeks gains - even if it didn't get to .17 like I thought. Though it did touch it there in the last few minutes.
I feel like the closer and closer to 2018 (the year of legalization) the more that momentum and news of legalization will help this retain its value and go up.
Good luck to all!!!
I hope so!!!!! $0.23
will fall back again but that doesn't worry me ... will be over 0.20 in a few weeks
Considering it went up 25-30% so far this week, if it mostly holds and doesn't sell off today, that wont be too bad.
I think though there might be some end of day buying and just creeps over .17.
But I have been wrong before.
Go ATTBF!!!
looking like we hit our top-side resistance here .165
Looks like the moves are once again coming to ATTBF
nice close – wonderful green
ATTBF
Agree – but we need more volume
I hope the 8-15% daily gains remain the trend.
Big huge 30%+ gaps up just lead to volatility if you ask me.
I wouldn't mind seeing a steady climb.
That Goldman research guy had it at .3 if I remember correctly so maybe this thing is trending to .3-.5 before it settles in.
Lets hope!!!!
Long ATTBF.
I was wondering the same thing, and with the launch of Vergence website....and everything else lining up behind them I think you could be right. It sure would be nice to be true...
ten years OTC I paid dearly – but also learned a lot ... especially to listen to my belly and mind this feeling in every respect before acting.
Abattis tastes like victory - but we all need a lot more patience* ATT is a slow torpedo ...
*unless you play the game of flippers and swingtraders ...
With legalization getting closer, I wonder if this means this company is ready to not look back - and by that I mean not dip back down to dime territory.
Go ATTBF - been in this thing for a VERY long time. Yes I am a bagholder but have averaged by price down!!!
Lvannoy88 Could just call some numbers now - but as I try to be honest, I would rather keep these numbers for me. Please be not disappointed - well ... my breakeven point I have reached. And I will keep this stock for a longer time.
This stock is still at the beginning of its career and I look forward to the summer of next year!
Guay,
if you don't mind my asking....how many shares you holding at what buy in?
im sitting on 210K at .133
"Abattis Bioceuticals Corp. is set to make some major inroads with its licensed testing and timely extraction capabilities - one of the only public companies with this complete skill set."
http://usanewsgroup.com/2017/09/11/biotech-sector-poised-to-deliver-more-health-and-wealth-2-2-2/
Marijuana Companies: Momentum on Their Side
9:00 am ET September 14, 2017 (PR Newswire) Print
USA News Group - Canada's first-mover Cannabis companies are taking the lead in moving from cannabis concept to the revenue producers. Companies making gains include: Canopy Growth Inc. (OTC: TWMJF) (TSX: WEED) Aurora Cannabis (OTC: ACBFF) (TSX: ACB) Aphria Inc. (OTC: APHQF) (TSX: APH) and Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT).
As most investors already recognize, Canada has taken the early lead in the move towards legalization of marijuana. The calendar is set to lift prohibition in mid-2018 under the current government there.
First mover companies who are anticipating the change are moving at an ever increasing pace to stake their positions and grab market share in what may be the hay day for cannabis stocks.
Markets are embracing the trend and rewarding companies that show the ability to make real advances and grow revenue.
Early participants on the leading edge include Abattis Bioceuticals Corp. (CSE: ATT.CN) (OTCQB: ATTBF), which is set to make some major inroads with its licensed testing and timely extraction capabilities - one of the only public companies with this complete skill set.
On the production side, Canopy Growth Inc. (TSX: WEED.TO) (OTC: TWMJF) is one of the stars, soaring to as high as $13 per share in February of 2017, only to fall more than 40% to under $8 in May of this year.
Other licensed cannabis companies who are right on pace include Aurora Cannabis (TSX-V: ACB.V) (OTCQX: ACBFF), and Aphria Inc. (TSX-V: APH.V) (OTCQB: APHQF) who are each closing in on the $1 billion market cap mark.
These players fall into the mega-producer category with massive facilities to grow and produce cannabis, with the exception of Abattis, who have smartly positioned themselves to become the go-to testing and research provider handling the needs of all cannabis producers.
UNPRECEDENTED GROWTH
Even at this relatively early stage, it is evident that the cannabis industry is experiencing nearly unprecedented growth. The value being generated as a result is exceptional - heading for CAGR projected as high as 25% through 2025. Beyond the plant's basic use through straight consumption, medicinal or recreational, are several other derivatives that provide major potential for the industry as a whole. North American marijuana sales grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a new report by Arcview Market Research. North American sales are projected to top $20.2 billion by 2021 assuming a compound annual growth rate of 25%. The report includes Canada for the first time as it moves towards implementing legal adult use marijuana. The market for CBD alone hit $170 million in 2016, and is projected to grow $1 billion by 2020 . To reach these kind of massive numbers, the industry is going to need a lot of independent firms doing research and coming up with new and better extraction methods, formulations and enormous testing capacity.
HEDGING ON RESEARCH AND TESTING
The global cannabis testing market is expected to grow at a CAGR of 11.5%, culminating towards a $1.42 billion market by 2021. This makes sense, since in order to deliver on big volumes, producers will need an accurate reading of the drug's potency, including the levels of the key medicinal components of cannabis, THC and CBD. Producers all recognize that this will require a skilled and specialized third party to test their product before it goes to market. This is the segment targeted directly by newcomer Abattis Bioceuticals. The company has a full spectrum lab staffed with industry experts to ensure the quality standard required by producers and developers. Its subsidiary, Northern Vine Labs, will not be limited for testing, however. Another major component to the facility will be in extraction and formulation. This means that the company will be involved in innovation of methods to extract medicinal components from cannabis on a massive industrial scale, and to formulate them for consumer products. Research will become a critically important part of this industry as it grows.
ATT'S SWEET SPOT
All the growth and attention being paid to testing have put leading edge companies like ATT at the forefront. ATT for instance, is establishing multiple assets to become Canada's cannabis testing, formulation and extraction facility of choice. Most of the companies in the cannabis space have entered through the producer's side of the business either cultivation or some aspect of production and distribution. Certainly the Canopy, Aurora, Aphria and others have focused on production. This has created a large and potentially very profitable opening for those companies applying bioscience and technology on the leading edge of the cannabis business. Even some of the mega stars have yet to tap into an even greater potential resource... one that's at the center of up and comer Abattis Bioceutical Corp.'s agenda. Abattis Bioceuticals and its majority-owned subsidiary Northern Vine Labs have merged efforts to create a state-of-the-art testing and research company, supported by its fully licensed labs that provide for legal cannabis testing and formulations. These combined operations will be one of the most sophisticated, Health Canada licensed operations in the country with the potential to handle virtually all forms of Cannabis testing and extraction development. Through its unique position as one of only very few labs granted the licensing needed to test cannabis, ATT is securing its future in the cannabis sector. With the addition Northern Vine Labs for research and products through Vergence, the company is also opening its services to a very broad spectrum. At this point it has the assets in place to vault its way up that of major status among the Auroras, Aphrias, and Canopys that are emerging. Those companies range from $800 million to $1.5 billion in market caps. Abattis Bioceuticals appears undervalued by comparison at a mere $24 million market cap. ATT has diversified its operations into several segments, from research and certification in its testing and lab facilities, to formulations and extracts exclusive to Northern Vine Labs and to products provided by its Vergence subsidiary. Although only recently established as a full spectrum R&D cannabis sector company, ATT has managed to bring together very valuable assets while tripling its price from a year ago. With the early interest and pent up demand for services, Abattis Bioceuticals looks like a serious leader as the cannabis sector seeks to build its infrastructure.
POTENTIAL COMPARABLES
Aphria (TSXV: APH) (OTCQB: APHQF)
Aphria Inc., boasts itself as one of Canada's lowest cost producers, that produces, supplies and sells medical cannabis. Located in the greenhouse capital of Canada, Leamington, Ontario, Aphria provides pharma-grade medical cannabis, and quality patient care. Aphria was the first public LP to report positive cash flow from operations, and the first to report positive earnings in consecutive quarters.
Aurora Cannabis (TSXV: ACB) (OTCQX: ACBFF)
Through its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., Aurora Cannabis is a major LP, operating a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta. Aurora made waves when it announced the construction of its 800,000 square foot "Aurora Sky" facility second 800,000 square foot production facility at the Edmonton International Airport. Aurora's also involved in Quebec, with its third 40,000 square foot production facility set to be completed in Pointe-Claire, Quebec, on Montreal's West Island. Aurora also holds a minority stake in leading extraction technology company Radient Technologies Inc., based in Edmonton, and a minority stake in Australian company Cann Group Limited, which was the first in Australia to conduct research on and cultivate medical cannabis. Aurora also owns German wholesale importer, exporter, and EU medical cannabis distributor Pedanios.
Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF)
The granddaddy of the corporate cannabis sector, Canopy Growth is the world's largest diversified cannabis company. Canopy boasts a wide offering of distinct brands and curated cannabis varieties in dried, oil and capsule forms. Most widely recognized is Canopy's subsidiary Tweed which is the world's most recognized marijuana production brand, as well as an industry educator. Accompanying Tweed in Canopy's portfolio is medical-grade cannabis producers Bedrocan Canada. In total, Canopy Growth's numerous state-of-the-art production facilities total over half a million square feet of GMP-certified indoor and greenhouse production capacity.
For a more in-depth look into ATT you can view the in-depth report at USA News Group: http://usanewsgroup.com/2017/09/11/biotech-sector-poised-to-deliver-more-health-and-wealth-2-2-2
so remember, remember to sell in november ...
#ATTBF: Starting to rock....
I'll beat you to the punch and sell at $0.23
Hahahahahahahahaha
Don't miss your exit stop ebota - remember 0.25! ... Everyone here wants you to be happy again!
Good NEWS +++ Vergence Naturals is Online +++
http://www.nasdaq.com/press-release/abattis-provides-important-update-on-northern-vine-and-sales-division-20170913-00739
"We are a natural product management company for some of the worlds best, naturally inspired, health & beauty brands for the conventional and cannabinoid markets"
This isn't actually "fluff", it's some kind of progress at least.
A fluff piece is when they pay someone to pump up their stock. Giving away equity was stupid, BT hey...what's another quarter million shares between friends?
this could be a big catalyst to get this stock moving....really moving
In my mail box today:
View this email in your browser
Abattis provides important update on Northern Vine and Sales Division
VANCOUVER, BRITISH COLUMBIA / September 13, 2017 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to provide an important update regarding its subsidiaries Northern Vine Canada Inc. (“Northern Vine”) and Vergence Naturals Ltd. (“Vergence”).
“We are very pleased with the continued progress being made to strengthen to the sales, marketing and distribution arm of Abattis and Northern Vine.” said Rob Abenante, President and CEO of Abattis. “We believe that the major value to be derived from the legal cannabinoid space will come from all downstream products and services derived from the cannabis plant. Vergence will be a direct gateway to sell products formulated at our labs in Northern Vine as well as others products which we are able to infuse with customized cannabinoid formulas. Abattis is equipped to service both of these rapidly evolving market’s and be fully prepared to be a market leader when recreational laws are passed.”
Website Launch and Online Retail Opportunity
Abattis is pleased to announce the official launch of the Vergence retail website, VergenceNaturals.com. The website is designed to streamline availability of the Vergence’s product lines, both developed in-house by Northern Vine and Abattis, as well as third-party products with which Vergence has distribution agreements. VergenceNaturals.com is a full-suite natural health products online store, through which all of Vergence’s products will eventually be featured and for sale.
“We’re very excited to launch VergenceNaturals.com, which should deliver not only sales revenue, but also important data on customer metrics for our carried lines,” said Mark Mansfield, VP of Sales at Vergence. “We see this sales portal as our Amazon, driving our goal is to be the go-to online retail location for natural health products. We look forward to the potential of incorporating Northern Vine’s CBD-infusion capabilities with not only the products we develop in-house, but with those we’ve signed distribution and marketing agreements with.”
Brands currently featured on the website include:
· Mogiana Coffee
· Jonny Hetherington
· Natrihealth
· Planet Hemp
· Beyond Silver
· Real Aloe
· Styrian Gold
· Maui Vera
In congruence with the launch of the website, Abattis is proud to announce the following sequence of distribution agreements signed by Vergence Naturals with high-quality third parties:
Distribution Agreement with Styrian Gold BC Inc.
Vergence has reached a global distribution agreement with Styrian Gold BC Inc., makers of the award-winning, 100% pure and unrefined Styrian Gold Pumpkin Seed Oil.
Styrian Gold Pumpkin Seed Oil delivers healthy antioxidants, vitamins and minerals vital for bodily functions. Consumption of the oil helps to aid the liver, bladder, urinary tract, and prostate, as well as having anti-inflammatory, anti-parasitic, and anti-diabetic benefits. Along with the oils, Styrian Gold also sells seeds and protein powder that it imports directly from an established and reputable oil pressing company in Styria.
Vergence will use its distribution and marketing channels to properly spread Styrian Gold products to global markets, and is proud to incorporate the line in its portfolio of products.
Distribution Agreement with Cascadia Soap Company
Vergence has reached a major North American distribution agreement with Cascadia Soap Company (or “Cascadia”), makers of natural skin care products under the same brand name.
Cascadia’s soaps, remedies, and infusions are made using classic artisan methods used for generations in the South of France. Along with all-natural ingredients such as rose hips, and dandelions to make the required salves and balms, Cascadia’s founder Joel Morassutti developed a technique to incorporate goat milk in the production of the company’s rich, long-lasting, and moisturizing cleansing bars. Goat milk is used to increase the health benefits of the milk’s liposomes in the soap.
Vergence has already listed the Cascadia Soaps best sellers on its new website, and is set to begin working on global distribution with partnered distributors.
Distribution Agreement with Naturally Canadian Foods
Vergence has signed a global distribution deal with Naturally Canadian Superfoods Inc., direct importers, distributors, and brokers of several products including Realoe, Maui Vera, and the hemp superfood line Planet Hemp.
“Key to the deal is the potential to co-develop products with Naturally Canadian Superfoods’, through our subsidiary, Northern Vine,” said Rob Abenante, President and CEO of Abattis. “We believe there is major potential for synergistic product lines still-to-be develop between Northern Vine and our new partners, through enhancement of formulas with the medical benefits of CBD oils.”
Naturally Canadian Superfoods’s product lines include natural and organic aloe vera sun care and lotion product lines Realaloe and Maui Vera, as well as hemp superfood line Planet Hemp, a natural buckwheat seaweed product line, a spice line from India, and an organic garden hose line, among other products.
Distribution Agreement with Smartpep Canada Biological Tech (DBA Natrihealth)
Vergence has signed a global distribution agreement with Smartpep Canada Biological Tech (DBA) Natrihealth (or “Smartpep”), for the “Natrihealth” brand of collagen supplements. Smartpep brings with it previously forged partnerships in North America, Asia, Japan, Korea, and Hong Kong among its markets, and boasts only the best, high-quality ingredients in its products.
The “Natrihealth” brand produces several collagen supplements, utilizing tripeptide technology. Unlike most collagen supplements on the market which are mass produced cheaply using beef and poultry, Natrihealth has focused on a higher quality fish-based formula.
“We are adding new brands to the website every week”, adds Andrea Bates, COO of Vergence Naturals, “…and we are very excited about the development of our own high end Vergence product lines. For example, we are currently working on a line of premium wild BC honeys, a luxury all natural, organic plant based cosmetic line and a CBD sunscreen which is being developed by our lab, Northern Vines.”
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.
About Vergence Naturals Ltd.
Vergence Naturals TM is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP.
“Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the expected volume of sales of the Johnny Hetherington Hot Sauce and Ketchup products through distribution channels in Asia and North America; the build-up of retail presence nationally and internationally over time; the standards and quality of Vergence products; the addressing of health and dietary concerns; the suitability of the products for a healthy lifestyle; the ingredients in the products; the quality and safety of the products; and, the shelf life of the products. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the Johnny Hetherington products or other products sold via Abattis or Vergence may not sell as expected or at all, the Company may be unsuccessful in developing new product formulations in the time expected or at all, the Company may not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues, the Company’s competitors may develop competing technologies (such competitors may also have greater financial resources and are able to affect their business plan more rapidly), changes in regulatory requirements and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where as a result of new information, future events or results, or otherwise, except as required by applicable securities laws.
Copyright © 2017 Abattis Bioceuticals Corp., All rights reserved.
Our mailing address is:
#224 - 970 Burrard St., Vancouver, BC V6K 2Z4
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
This email was sent to mchinard@gmail.com
why did I get this? unsubscribe from this list update subscription preferences
Abattis Bioceuticals Corporation · 224 - 970 Burrard St. · Vancouver, BC V6K 2Z4 · Canada
Email Marketing Powered by MailChimp
This fluff piece cost $10,000 CAD and 250,000 shares. That's sickening.
For some time we see a slow but steady ATTBF share price increase and a higher trading volume than usual. Is this a good sign? - I think so!
a lot of buying going on today...405K @ .122...hmmmm
FIRST TIME IN A WHILE ITS NOT INDICATING "SELL"
https://www.americanbulls.com/m/SignalPage.aspx?lang=en&Ticker=ATTBF
Biotech sector poised to deliver more health and wealth
http://usanewsgroup.com/2017/09/06/biotech-sector-poised-to-deliver-more-health-and-wealth-2-2/
Sounds like a good question to ask the company.
@StarFishPatrick#30249
What private placement? Why did they choose not to participate?
it would be great if they got the 100% or a partner to enter the other 50%...I would imagine property zoned to cultivate is a nice asset to have....
Interesting - Any thoughts ? On April 27, 2017, the Company entered into a LOI with respect to a joint venture on a piece of property in Oroville Washington, zoned for cultivation. As part of the potential JV process, $127,202.84 was forwarded in consideration of 50% joint ownership in the property. Due diligence revealed that the joint venture would not be complimentary to Abattis' business plan. Accordingly, any further negotiations were terminated. Presently, Abattis is on title as a 50% owner of the property and working toward either exercising a power of sale or realising a 100% ownership in the property with no further cost to Abattis.
Just want to point out on page 12 - Abattis owns 18.75% of Experion. You'll note that this is less than the 25% as part of the original deal. The drop in ownership is because Abattis chose not to participate in an Experion private placement last fall and their ownership was diluted. Perhaps you will believe me in the future since I've usually been proven correct.
Still no revenue. What a turd.
Not sure if this was posted already, but came out last week on SEDAR...
http://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00011477&issuerType=03&projectNo=02670345&docId=4174481
ATTBF !! BACK-IN !! GOING TO BE A GREAT WEEK !!
Followers
|
324
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
32851
|
Created
|
01/22/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |